Episode Details

The FDA recently cleared the Artificial Intelligence Renal Assessment AIRA Version 1 for measuring kidney volume from CT scans. We break down the device's technical workflow, its impressive clinical performance metrics, and the strict regulatory controls required for AI software in medical imaging.

Key points

• AIRA Version 1 received Class II clearance for automatic image segmentation and calculation of renal parenchymal volume using CT scans.
• The algorithm's performance was validated in a retrospective standalone study of 113 cases, achieving a mean Dice Similarity Coefficient of 0.9092 for the right kidney and 0.9114 for the left.
• The study intentionally enriched its sample so that at least 25% of cases featured atrophied kidneys, ensuring the tool works on diseased anatomy.
• AIRA demonstrated substantial equivalence to the predicate device, Ceevra Reveal 3, but opted for a narrower focus: CT imaging only and limited to the kidney.
• The FDA clearance underscores the heavy quality management and regulatory requirements for Software as a Medical Device, including strict ISO 13485 design controls.

Source: Artificial Intelligence Renal Assessment (AIRA) Version 1 - U.S. Food and Drug Administration, 2026

This spot is available. Reach clinicians, health-system leaders and medtech and pharma teams following AI in medicine. Sponsor the show

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/unpacking-the-fda-clearance-of-the-aira-kidney-algorithm-ed2d94